June 14, 2022
Indies Pharma Jamaica Limited (INDIES), for the six months ended April 30, 2022, reported revenue of $462.88 million, 9% higher than the $424.25 million booked in 2021. For the second quarter, revenue closed at $250.58 million (2021: $200.72 million).
Cost of sales, for the six months ended April 30, 2022, decline by 23% to close at $127.37 million (2021: $166.38 million). This resulted in gross profit increasing by 30%, amounting to $335.52 million for the six months relative to $257.87 million reported in the previous corresponding period. For the second quarter ended April 30, 2022, gross profit closed at $178.53 million (2021: $119.76 million).
Other operating income, for the six months ended April 30, 2022, increased by 106% to close at $730,695 (2021: $355,186). Additionally, administrative and other expenses increased by 19% closing at $191.46 million in 2022 from $160.41 million booked twelve months earlier. For the quarter, administrative and other expenses closed at $99.04 million (2021: $85.52 million).
As such, operating profit, for the six months ended April 30, 2022, rose by 48% totalling $144.79 million (2021: $97.82 million). For the quarter, operating profit amounted to $79.78 million versus $34.38 million recorded in the prior comparable quarter. Exchange loss for the six months amounted to $275,058 relative to a gain of $1.19 million booked in the 2021. Finance cost for the six months ended April 30, 2022 amounted to $29.86 million (2021: $31 million).
Profit before taxation increased by 69% to close the six months ended April 30, 2022 at $ 114.65 million (2021: $68.01 million). For the quarter, profit before taxation amounted to $64.12 million compared to $20.49 million in the previous corresponding quarter.
Net profit, for the six months ended April 30, 2022, closed at $114.65 million (2021: $68.01 million). While for the quarter, net profit totalled $64.12 million (2021: $20.49 million).
Total comprehensive income for the six months ended April 30, 2022 amounted to $114.65 million (2021: $69.33 million) and closed at $64.12 million (2021: $21.81 million) for the quarter ended April 30, 2022.
Consequently, earnings per share (EPS) for the six months amounted to $0.086 (2021: $0.051). While for the quarter, earnings per share closed at $0.048 (2021: $0.015). The trailing twelve months earnings per share amounted to $0.17. The numbers of shares used in the calculations are 1,332,536,649 units. Notably, INDIES stock price closed the trading period on June 13, 2022 at $3.06 with a corresponding P/E of 18.11 times.
Balance Sheet at a glance:
As at April 30, 2022, the Company’s total asset base amounted to $2.25 billion (2021: $1.67 billion). The increase is mainly due to ‘Property, Plant and Equipment’ which closed at $944.40 million (2021: $650.23 million). ‘Cash and Cash Equivalents’ also contributed to the growth closing at $260.25 million (2021: $84.87 million). However, the movement was affected by a decline in ‘Investment’ and ‘Receivables’ to $121.02 million (2021: $302.24 million) and $180.71 million (2021: $218.13 million) respectively.
Equity attributable to stockholders of parent amounted to $1.07 billion (2021: $709.49 million) with book value per share amounting to $0.80 (2021: $0.53).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
